首页> 外国专利> VELDOREOTIDE WITH POOR SOLUBITLIY IN PHYSIOLOGICAL CONDITIONS FOR USE IN THE TREATMENT OF ACROMEGALY, ACROMEGALY CANCER, SST-R5 EXPRESSING TUMORS, TYPE 2 DIABETES, HYPERGLYCEMIA,AND HORMONE-RELATED TUMORS

VELDOREOTIDE WITH POOR SOLUBITLIY IN PHYSIOLOGICAL CONDITIONS FOR USE IN THE TREATMENT OF ACROMEGALY, ACROMEGALY CANCER, SST-R5 EXPRESSING TUMORS, TYPE 2 DIABETES, HYPERGLYCEMIA,AND HORMONE-RELATED TUMORS

机译:在生理条件下可溶性较弱的维多柔太肽,用于治疗角膜病,角膜癌,SST-R5表达肿瘤,2型糖尿病,高糖血症和与激素相关的肿瘤

摘要

The present invention provides compositions comprising water soluble peptides with poor solubility in isotonic solutions which exhibit enhanced bioavailability with reduced adverse effects including injection site reactions. Methods are also disclosed for using such compositions for the treatment of diseases including, but not limited to, cancer, type 2 diabetes, acromegaly, metabolic disorders, endocrine disorders, exocrine tumors, and hormone-related tumors. Methods to reduce adverse injection site reactions and improve bioavailability are also disclosed.
机译:本发明提供了包含在等渗溶液中溶解性差的水溶性肽的组合物,其显示出提高的生物利用度并且减少了包括注射部位反应在内的不良影响。还公开了使用此类组合物治疗疾病的方法,所述疾病包括但不限于癌症,2型糖尿病,肢端肥大症,代谢紊乱,内分泌失调,外分泌肿瘤和激素相关肿瘤。还公开了减少不良注射部位反应并改善生物利用度的方法。

著录项

  • 公开/公告号CA3014406A1

    专利类型

  • 公开/公告日2017-08-24

    原文格式PDF

  • 申请/专利权人 STRONGBRIDGE BIOPHARMA PLC;

    申请/专利号CA20173014406

  • 发明设计人 AFARGAN MICHAEL;

    申请日2017-02-16

  • 分类号A61K47/40;A61K9;A61K9/16;A61K38/08;A61K47/26;A61K47/34;A61K47/36;A61P3;A61P5;A61P35;

  • 国家 CA

  • 入库时间 2022-08-21 13:34:09

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号